Journal of Shandong University (Health Sciences) ›› 2023, Vol. 61 ›› Issue (12): 62-69.doi: 10.6040/j.issn.1671-7554.0.2023.0738

• The innovation and challenge of artificial intelligence in medical imaging-Clinical Research • Previous Articles    

Radiomics of enhanced CT in predicting the response to platinum-based chemotherapy for ovarian cancer

JIAO Guangli1, SHI Zixin1, CHEN Rong1, SONG Yabo1, YANG Fei2, CUI Shujun2   

  1. 1. Graduate School, Hebei North University, Zhangjiakou 075000, Hebei, China;
    2. Department of Imaging, The First Affiliated Hospital of Hebei North University, Zhangjiakou 075000, Hebei, China
  • Published:2024-01-11

PDF (PC)

116

Abstract: Objective To construct and compare the performance of clinical model, radiomics model and combined model in predicting the patients response to platinum-based chemotherapy for ovarian cancer(OC). Methods The complete data of 94 OC patients confirmed by pathology were retrospectively analyzed. The 2D-ROI and 3D-ROI of tumors were sketched along the tumor contour on the venous phase images, and then radiomics features were extracted and dimensionality reduction filtering was performed. After the radscore was calculated, 2D and 3D radiomics models were constructed, and their prediction efficiency was compared. Meaningful clinical features were retained to build a clinical model, and then radscore was added to construct a combined model. The predictive efficacy of clinical, radiomics and combined models was evaluated with the receiver operating characteristic(ROC)curve, calibration curve, and decision analysis curve(DCA). Results The 3D model showed higher predictive efficiency than 2D model, with the area under ROC curve(AUC)being 0.766 and 0.677, respectively. Compared with the clinical model(age, RT)and radiomics model, the combined model showed the best predictive efficacy, with the AUC being 0.708, 0.766, and 0.827, respectively(P=0.010). Conclusion Modeling based on enhanced CT radiomics and clinical features can predict OC patients response to platinum-based chemotherapy, and the combined model has high predictive efficacy.

Key words: Ovarian cancer, Radiomics, Enhanced CT, Platinum-based chemotherapy, Response to platinum-based chemotherapy

CLC Number: 

  • R445.3
[1] An Y, Yang Q. Tumor-associated macrophage-targeted therapeutics in ovarian cancer [J]. Int J Cancer, 2021, 149(1): 21-30. doi: 10.1002/ijc.33408.
[2] Havasi A, Cainap SS, Havasi AT, et al. Ovarian cancer-insights into platinum resistance and overcoming it [J]. Medicina(Kaunas). 2023, 59(3): 544. doi: 10.3390/medicina59030544..
[3] Konstantinopoulos PA, Matulonis UA. Clinical and translational advances in ovarian cancer therapy [J]. Nat Cancer. 2023, 4(9): 1239-1257. doi: 10.1038/s43018-023-00617-9.
[4] 王芳, 夏雨薇, 柴象飞, 等. 影像组学分析流程及临床应用的研究进展[J]. 中华解剖与临床杂志, 2021, 26(2): 236-241. WANG Fang, XIA Yuwei, CHAI Xiangfei, et al. Analysis process and clinical application of radiomics [J]. Chinese Journal of Anatomy and Clinics, 2021, 26(2): 236-241.
[5] Kann BH, Hosny A, Aerts HJWL. Artificial intelligence for clinical oncology [J]. Cancer Cell. 2021, 39(7): 916-927.
[6] 魏明翔, 柏根基, 郭莉莉. 影像组学在卵巢肿瘤中的研究进展[J]. 磁共振成像, 2020, 11(5): 386-389. WEI Mingxiang, BO Genji, GUO Lili. The research progress of radiomics in ovarian tumors [J]. Chinese Journal of Magnetic Resonance Imaging, 2020, 11(5): 386-389.
[7] 毛咪咪, 李海明, 石健, 等. 基于多序列MRI影像组学列线图预测上皮性卵巢癌患者对铂类药物化疗的敏感性[J]. 中华医学杂志, 2022, 102(3): 201-208. MAO Mimi, LI Haiming, ShI Jian, et al. Prediction of platinum based chemotherapy sensitivity for epithelial ovarian cancer by multi sequence MRI based radiomic nomogram [J]. National Medical Journal of China, 2022, 102(3): 201-208.
[8] Lu J, Li HM, Cai SQ, et al. Prediction of platinum-based chemotherapy response in advanced high-grade serous ovarian cancer: ADC histogram analysis of primary tumors [J]. Acad Radiol, 2021, 28(3): e77-e85.
[9] Veeraraghavan H, Vargas HA, Jimenez-Sanchez A, et al. Integrated multi-Tumor radio-genomic marker of outcomes in patients with high serous ovarian carcinoma [J]. Cancers(Basel), 2020, 12(11): 3403. doi: 10.3390/cancers12113403.
[10] Wilson MK, Pujade-Lauraine E, Aoki D, et al. Fifth ovarian cancer consensus conference of the gynecologic cancer interGroup: recurrent disease [J]. Ann Oncol, 2017, 28(4): 727-732.
[11] 王雪, 张广美, 何征秦. 复发性卵巢癌的药物治疗及进展[J]. 中国现代医学杂志, 2021, 31(1): 38-44. WANG Xue, ZhANG Guangmei, HE Zhengqin. Drug treatment and research progress of recurrent ovarian cancer [J]. China Journal of Modern Medicine, 2021, 31(1): 38-44.
[12] Li SY, Liu JQ, Xiong YH, et al. A radiomics approach for automated diagnosis of ovarian neoplasm malignancy in computed tomography [J]. Sci Rep, 2021, 11(1): 8730. doi: 10.1038/s41598-021-87775-x.
[13] Zhu H, Ai Y, Zhang J, et al. Preoperative nomogram for differentiation of histological subtypes in ovarian cancer based on computer tomography radiomics [J]. Front Oncol, 2021, 11: 642892. doi: 10.3389/fonc.2021.642892.
[14] anala G, Thai T, Gunderson CC, et al. Applying quantitative CT image feature analysis to predict response of ovarian cancer patients to chemotherapy [J]. Acad Radiol, 2017, 24(10): 1233-1239.
[15] Jian J, Li Y, Pickhardt PJ, et al. MR image-based radiomics to differentiate type Iota and type iotaIota epithelial ovarian cancers [J]. Eur Radiol, 2021, 31(1): 403-410.
[16] Li C, Wang H, Chen Y, et al. Nomograms of combining MRI multisequences radiomics and clinical factors for differentiating high-grade from low-grade serous ovarian carcinoma [J]. Front Oncol, 2022, 12: 816982. doi: 10.3389/fonc.2022.816982.
[17] Yi X, Liu Y, Zhou B, et al. Incorporating SULF1 polymorphisms in a pretreatment CT-based radiomic model for predicting platinum resistance in ovarian cancer treatment [J]. Biomed Pharmacother, 2021, 133: 111013. doi: 10.1016/j.biopha.2020.111013.
[18] Kazerooni AF, Malek M, Haghighatkhah H, et al. Semiquantitative dynamic contrast-enhanced MRI for accurate classification of complex adnexal masses [J]. J Magn Reson Imaging, 2017, 45(2): 418-427.
[19] Rizzo S, Botta F, Raimondi S, et al. Radiomics of high-grade serous ovarian cancer: association between quantitative CT features, residual tumour and disease progression within 12 months [J]. Eur Radiol, 2018, 28(11): 4849-4859.
[20] Qiu Y, Tan M, McMeekin S, et al. Early prediction of clinical benefit of treating ovarian cancer using quantitative CT image feature analysis [J]. Acta Radiol, 2016, 57(9): 1149-1155.
[21] Mayerhoefer ME, Materka A, Langs G, et al. Introduction to radiomics [J]. J Nucl Med, 2020, 61(4): 488-495.
[22] 刘鹏, 王丽嘉, 马超. 影像组学及分析工具浅谈[J]. 生物医学工程与临床, 2022, 26(4): 511-518. LIU Peng, WANG Lijia, MA Chao. Introduction of radiomics and analytical tools [J]. Biomedical Engineering and Clinical Medicine, 2022, 26(4): 511-518.
[23] 潘淑淑, 沈起钧, 陈文辉, 等. 增强CT影像组学鉴别卵巢良性与交界性浆液性肿瘤[J].中国介入影像与治疗学, 2020, 17(6): 355-359. Pan Shushu, Shen Qijun, Chen Wenhui, et al. Radiomic of enhanced CT for identification of benign and borderline serous tumors of ovary [J]. Chinese Journal of Interventional Imaging and Therapy, 2020, 17(6): 355-359.
[24] Vargas HA, Veeraraghavan H, Micco M, et al. A novel representation of inter-site tumour heterogeneity from pre-treatment computed tomography textures classifies ovarian cancers by clinical outcome [J]. Eur Radiol, 2017, 27(9): 3991-4001.
[25] Mingzhu L, Yaqiong G, Mengru L, et al. Prediction of BRCA gene mutation status in epithelial ovarian cancer by radiomics models based on 2D and 3D CT images [J]. BMC Med Imaging, 2021, 21(1): 180. doi: 10.1186/s12880-021-00711-3.
[26] Li S, Liu J, Xiong Y, et al. Application values of 2D and 3D radiomics models based on CT plain scan in differentiating benign from malignant ovarian tumors [J]. Biomed Res Int, 2022, 2022: 5952296. doi: 10.1155/2022/5952296.
[27] Winarno GNA, Pasaribu M, Susanto H, et al. The platelet to lymphocyte and neutrophil to lymphocyte ratios in predicting response to platinum-based chemotherapy for epithelial ovarian cancer [J]. Asian Pac J Cancer Prev, 2021, 22(5): 1561-1566.
[28] Karam A, Ledermann JA, Kim JW, et al. Fifth ovarian cancer consensus conference of the gynecologic cancer Intergroup: first-line interventions [J]. Ann Oncol, 2017, 28(4): 711-717.
[29] Braman N, Prasanna P, Whitney J, et al. Association of peritumoral radiomics with tumor biology and pathologic response to preoperative targeted therapy for HER2(ERBB2)-positive breast cancer [J]. JAMA Netw Open, 2019, 2(4): e192561. doi: 10.1001/jamanetworkopen.2019.2561.
[30] Hu Y, Xie C, Yang H, et al. Assessment of intratumoral and peritumoral computed tomography radiomics for predicting pathological complete response to neoadjuvant chemoradiation in patients with esophageal squamous cell carcinoma [J]. JAMA Netw Open, 2020, 3(9): e2015927. doi: 10.1001/jamanetworkopen.2020.15927.
[31] 苏亚英, 石子馨, 张苗,等. 基于DCE-MRI影像组学定量预测进展期宫颈鳞癌同步放化疗反应的价值[J].河北北方学院学报(自然科学版),2023,39(2):11-17. SU Yaying, ShI Zixin,ZhANG Miao,et al. Value of Quantitative Prediction of Response to Concurrent Chemotherapy and Radiation Therapy in Advanced Cervical Squamous Cell Carcinoma Based on DCE-MRI Radiomics [J]. Journal of Hebei North University(Natural Sciences Edition), 2023, 39(2): 11-17.
[32] Chen M, Cao J, Hu J, et al. Clinical-radiomic analysis for pretreatment prediction of objective response to first transarterial chemoembolization in hepatocellular carcinoma [J]. Liver Cancer, 2021, 10(1): 38-51.
[1] JIN Xinjuan, ZUO Liping, DENG Zhanhao, LI Anning, YU Dexin. Value of enhanced MRI radiomics in predicting the drug-resistant protein PFKFB3 in 135 cases of hepatocellular carcinoma [J]. Journal of Shandong University (Health Sciences), 2023, 61(6): 79-86.
[2] HE Jing, YAN Rugen, WU Zhihong, LI Changzhong. Effects of Xiaozheng Yiai decoction on the proliferation and migration of ovarian cancer SKOV3 cells [J]. Journal of Shandong University (Health Sciences), 2023, 61(5): 1-10.
[3] LIU Yan, LENG Shanshan, XIA Xiaona, DONG Hao, HUANG Chencui, MENG Xiangshui. Functional outcomes of 376 patients with supratentorial spontaneous intracerebral hemorrhage based on radiomic parameters [J]. Journal of Shandong University (Health Sciences), 2023, 61(5): 59-67.
[4] ZHU Zhengyang, SHEN Jingfei, CHEN Sixuan, YE Meiping, YANG Huiquan, ZHOU Jianan, LIANG Xue, ZHANG Xin, ZHANG Bing. Prediction of isocitrate dehydrogenase mutation in glioma with different radiomic models based on susceptibility-weighted imaging [J]. Journal of Shandong University (Health Sciences), 2023, 61(12): 44-50.
[5] GAO Lin, YU Xinxin, KANG Bing, ZHANG Shuai, WANG Ximing. Predictive value of CT-based radiomics nomogram for the invasiveness of lung pure ground-glass nodules [J]. Journal of Shandong University (Health Sciences), 2022, 60(5): 87-97.
[6] DONG Liang, CUI Wenchao, ZHOU Qing, ZHANG Longyun, ZHOU Wei, ZHANG Xin, ZHAO Chao. Comparison of ultrasound and enhanced CT percutaneous puncture of mixed density chest lesions [J]. Journal of Shandong University (Health Sciences), 2022, 60(5): 98-103.
[7] YUAN Hongtao, JI Congshan, KANG Bing, QIN Songnan, YU Xinxin, GAO Lin, WANG Ximing. Diagnostic value of CT radiomics nomogram for adrenal lipid-poor adenoma and nodular hyperplasia [J]. Journal of Shandong University (Health Sciences), 2022, 60(4): 68-75.
[8] HA Chunfang, LI Ruyue. Research progress of drug resistance in ovarian cancer and targeted therapy strategy [J]. Journal of Shandong University (Health Sciences), 2021, 59(9): 117-123.
[9] SONG Zhenzhen, SUN Xiaoling, LI Haiou, WANG Fang, ZHANG Ran, YU Dexin. Value of MRI radiomics of glioma and peritumoral edema in evaluating tumor recurrence [J]. Journal of Shandong University (Health Sciences), 2021, 59(11): 53-60.
[10] WANG Zhengyang, XIA Yan, SHI Kaixuan, TAO Kun, WANG Xiaojie. Effects of Trametinib on PAX8 expression in ovarian cancer [J]. Journal of Shandong University (Health Sciences), 2021, 59(10): 25-31.
[11] YAN Qinghu, CUI Jia, YANG Chuanbin, WANG Wuzhang, YU Dexin, CHAI Xiangfei. Value of CT radiomics analysis of cavity characteristics in differentiating pulmonary disease of nontuberculous mycobacterium from tuberculosis [J]. Journal of Shandong University (Health Sciences), 2020, 58(6): 41-46.
[12] WANG Baojin, ZHAO Xinxin, LI Xia, MA Qian, WANG Xinyue, SUN Yang, SHI Zhongna. miR-203 targeting Survivin to inhibit the proliferation, migration and invasion of ovarian cancer cells [J]. Journal of Shandong University (Health Sciences), 2020, 58(12): 23-28.
[13] GUAN Hongwei, LI Juan, SUN Rui, LIU Jie, LI Changzhong. Biological effects of ubenimex on ovarian cancer A2780 cell [J]. Journal of Shandong University (Health Sciences), 2019, 57(12): 46-51.
[14] XUE Ting, WANG Liming, JIAO Jinwen, LI Yong, GUO Ailian, ZHAO Han. siRNA-mediated silencing of RRM2 in the treatment of epithelial ovarian cancer xenograft in nude mice [J]. Journal of Shandong University (Health Sciences), 2019, 57(10): 74-79.
[15] YANG Jiaxin, SHEN Keng, WANG Yao. Status and prospect of fertility preservation treatment for gynecologic malignancies [J]. Journal of Shandong University (Health Sciences), 2018, 56(5): 1-7.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd